Clinical trial NCT05573724: Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
Official title: A Non-randomized, Open-label, Fixed-sequence Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD5305 in Patients With Advanced Solid Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Malignancies
Keywords: Tumors
Pharmacokinetics
Itraconazole
AZD5305
Safety
Tolerability
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2022-10-10
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 130
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a single-arm, open-label, multi-centre drug-drug interaction (DDI) study of AZD5305 administered orally in patients with advanced solid tumours.

Detailed description: This study will comprise of two study parts, Part A and Part B. Part A of the study will assess the effect of multiple doses of Itraconazole on the single dose pharmacokinetic (PK) parameters of AZD5305 which will last up to 13 days. The patients will then continue into Part B and receive AZD5305 monotherapy at the discretion of the Investigator if the patients are deemed to still derive benefit from continued treatment until disease progression.

The Part A of this study follows a non-randomized, open-label, 2-intervention design. Patients will receive the following two study interventions, AZD5305 and Itraconazole: a single oral dose of AZD5305 alone, multiple oral doses of itraconazole alone, and then a single oral dose of AZD5305 administered concomitantly with multiple doses of itraconazole.

In Part B, the patients may continue the study with AZD5305 monotherapy after completing Part A of the study. AZD5305 monotherapy will continue until disease progression, unacceptable toxicities, initiation of alternative anticancer therapy, withdrawal of consent, or other reasons to discontinue study treatment occur.

Eligibility criteria: Inclusion Criteria:

* Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
* Males and females aged ≥ 18 years at the time of screening.
* Patients with documented evidence of locally advanced unresectable or metastatic solid tumours, excluding lymphoma, who have exhausted standard of care options (or for which no standard therapies exist) and may be suitable for AZD5305 monotherapy treatment.
* Adequate organ and marrow function.
* An Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0 to 2 with no deterioration over the previous 2 weeks.
* Life expectancy ≥ 12 weeks.
* Female patients of childbearing potential. Must have a negative pregnancy test result at screening and prior to each Part of study intervention.
* Female patients must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study intervention.

Exclusion Criteria:

* Previous enrolment in the present study (ie, dosing with AZD5305 previously initiated in this study).
* Positive for detection of drugs of abuse or alcohol at screening.
* Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 enzyme (CYP3A4) substrates, strong, and moderate inhibitors or inducers.
* Patients with germline Breast cancer gene-mutated relapsed advanced ovarian cancer who have received three or more previous lines of chemotherapy.
* Using of proton pump inhibitors, histamine H2 receptor antagonists and other antiacid agents.
* Using of calcium channel blockers.
* Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsade's de Pointes (TdP).
* During the 4 weeks prior to the first dose, receiving continuous corticosteroids.
* Major surgery within 4 weeks of the first dose of study intervention.
* Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study intervention.
* Treatment with any of the following: any investigational agents or study interventions from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study intervention; any other anticancer treatment within the following time periods prior to the first dose of study intervention: Cytotoxic and non-cytotoxic treatment: 3 weeks or five half-lives (whichever is shorter); Biological products including immuno-oncology agents: 4 weeks before enrolment.; any live virus or bacterial vaccine within 28 days of the first dose of study intervention.
* Any concurrent anticancer therapy or concurrent use of prohibited medications.
* With the exception of alopecia, and peripheral neuropathy; any unresolved toxicities from prior therapy greater than CTCAE Grade 1.
* Any known history of persisting (\> 2 weeks) severe pancytopenia.
* Spinal cord compression, or brain metastases unless asymptomatic and treated and stable and not requiring continuous corticosteroids at a dose of \> 10 mg prednisone/day or equivalent.
* Any evidence of severe or uncontrolled systemic diseases, including, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus.
* Patients with any known predisposition to bleeding.
* Any of the following cardiac criteria: mean resting QTcF \> 450 ms or QTcF \< 340 ms obtained from triplicate ECGs and averaged, recorded within 5 minutes; any factors that increase the risk of QT prolongation, shortening or risk of arrhythmic events such as hypokalaemia, congenital long or short QT syndrome, family history of long QT syndrome, familial short QT syndrome, or unexplained sudden death under 40 years of age; any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, second- or third-degree atrioventricular block, and clinically significant sinus node dysfunction not treated with pacemaker.
* Other cardiovascular diseases.
* Patients with history of MDS/AML or with features suggestive of MDS/AML.
* Refractory nausea and vomiting, chronic GI diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305.
* Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).
* Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study intervention or interpretation of patient safety or study results.
* Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
* Uncontrolled intercurrent illness within the last 12 months.

Primary outcomes:
measure: Part A: Area under the concentration-time curve from time zero to infinity (AUCinf)
timeFrame: Day 1-4, Day 7-13
measure: Part A: AUC from time zero to time of last measurable concentration (AUClast)
timeFrame: Day 1-4, Day 7-13
measure: Part A: Maximum plasma drug concentration (Cmax)
timeFrame: Day 1-4, Day 7-13
measure: Part A: Apparent total body clearance of drug from plasma (CL/F)
timeFrame: Day 1-4, Day 7-13
measure: Part A: Terminal elimination half-life (t½λz)
timeFrame: Day 1-4, Day 7-13
measure: Part A: Time to maximum observed concentration (Tmax)
timeFrame: Day 1-4, Day 7-13
measure: Part A: Apparent volume of distribution based on the terminal phase (Vz/F)
timeFrame: Day 1-4, Day 7-13
Secondary outcomes:
measure: Part A and Part B: Number of participants with Adverse Events (AEs) and Serious Adverse events (SAEs)
timeFrame: Part A: From screening until post-treatment follow-up (28 days after last dose) (approximately 13 days if continuing into Part B); Part B: From Cycle 1 day 1 until Post treatment follow up (28 days after last dose) (approximately 12 months)
measure: Part A and Part B: Number of Participants with Laboratory Value Abnormalities and/or AEs
timeFrame: Part A: From screening until post-treatment follow-up (28 days after last dose) (approximately 13 days if continuing into Part B); Part B: From Cycle 1 Day 1 until Post treatment follow-up (28 days after last dose) (approximately 12 months)
measure: Part A and Part B: Number of Participants with Vital Sign Abnormalities and/or AEs
timeFrame: Part A: From screening until post-treatment follow-up (28 days after last dose) (approximately 13 days if continuing into Part B); Part B: From Cycle 1 Day 1 until Post treatment follow-up (28 days after last dose) (approximately 12 months)
measure: Part A and Part B: Number of Participants with Electrocardiogram (ECG) Abnormalities and/or AEs
timeFrame: Part A: From screening until post-treatment follow-up (28 days after last dose) (approximately 13 days if continuing into Part B); Part B: From Cycle 1 Day 1 until Post treatment follow-up (28 days after last dose) (approximately 12 months)
measure: Part A and Part B: Number of Participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) Abnormalities and/or AEs
timeFrame: Part A: From screening until post-treatment follow-up (28 days after last dose) (approximately 13 days if continuing into Part B); Part B: From Cycle 1 Day 1 until Post treatment follow-up (28 days after last dose) (approximately 12 months)
Other outcomes:
Locations:
city: Chisinau
country: Moldova, Republic of
facility: Research Site
city: Cluj-Napoca
country: Romania
facility: Research Site
Study officials:
References: